Skip to main content

Moberg Pharma to present at Jefferies Global Healthcare conference November 20

Moberg Pharma’s CEO Peter Wolpert will present at the Jefferies 2014 Global Healthcare Conference on Thursday November 20, 2014, at 4:20 pm. Mr. Wolpert will discuss the Q3 results and the company’s growth strategy, Moberg Pharma’s phase 2 assets, including MOB-015 for which the company in September reported positive phase 2 results and the recently started phase 2 trial of BUPI in oral mucositis.

About Jefferies 2014 Global Healthcare Conference in London
The conference takes place at Waldorf Hilton Hotel in London November 19-20 and features public and private leading global pharmaceutical and biotech companies. This global gathering of institutional investors, private equity investors, VCs and leading executives will address near- and long-term investment opportunities and discuss the mechanisms driving global healthcare.

About Moberg Pharma AB
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with a direct sales and marketing organization in the U.S. and an extensive distributor network in more than 40 countries. The company’s OTC portfolio includes the brands Kerasal®, Jointflex®, Kerasal Nail®, Domeboro®, Vanquish®, and Fergon®. Kerasal Nail® (Nalox™ in certain ex-U.S. markets) is the leading product for the treatment of nail disorders in the U.S. and Nordic market. The current portfolio will be supplemented by the acquisition and in-licensing of additional products as well as product development with a focus on innovative drug delivery of proven compounds. Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares (OMX: MOB) are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: